Form 4: Forte Biosciences CFO Reports Stock Transactions
SEC Form 4 Filing
Antony A. Riley, CFO of Forte Biosciences, reports the vesting and disposal of restricted stock units.
Summary
- On April 1, 2025, Antony A. Riley, the Chief Financial Officer of Forte Biosciences, Inc., engaged in transactions involving the company's common stock.
- Riley acquired 375 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.
- Simultaneously, Riley disposed of 154 shares of common stock at a price of $7.43.
- Following these transactions, Riley directly owns 31,218 shares of Forte Biosciences common stock and 2,625 restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard reporting of stock transactions.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CFO's holdings.
Key Dates
| Date | Description |
|---|---|
| 02/01/2023 | First Quarterly Vesting Date for RSUs |
| 04/01/2025 | Date of stock transactions: RSU vesting and stock disposal |
| 04/02/2025 | Date of signature for the Form 4 filing |
Keywords
Forte Biosciences, FBRX, Form 4, Riley Antony A, CFO, Stock Transaction, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.